Nyxoah SA (NYXH) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PolyPid (PYPD) has outperformed Nyxoah SA (NYXH) over the past year, gaining 52.5% versus a loss of 78.7%. Over five years, NYXH leads with a -94.7% price change compared with -97.7% for PYPD. Nyxoah SA is the larger company by market cap ($138.5 million vs $103.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NYXH | PYPD |
|---|---|---|
| Share price | $1.36 | $5.07 |
| Market cap | $138.50M | $102.98M |
| 1-day change | +0.74% | +3.47% |
| YTD return | -70.43% | +16.82% |
| 1-year return | -78.72% | +52.48% |
| 5-year return | -94.67% | -97.75% |
| EPS (TTM) | $-2.56 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $5.73 |
| 52-week low | $1.26 | $3.10 |
| Distance from 52-week high | -79.39% | -11.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +208.82% | +131.76% |
| Average volume | 276.69K | 175.46K |
| Shares outstanding | 101.84M | 20.31M |
| Employees | 153 | 69 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed NYXH by 131.2 percentage points over the past year.
About Nyxoah SA
NYXH stock →Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
Health Care · Medical/Dental Instruments · 153 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Health Care · Medical/Dental Instruments · 69 employees
NYXH vs PYPD FAQ
Which is bigger, Nyxoah SA or PolyPid?
Nyxoah SA (NYXH) is larger, with a market capitalization of $138.50M compared with $102.98M for PolyPid (PYPD).
Which stock has performed better over the past year, NYXH or PYPD?
PYPD returned +52.48% over the past 12 months, compared with -78.72% for NYXH (price return, excluding dividends). Past performance does not predict future results.
Are Nyxoah SA and PolyPid in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.